Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 417 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group
Patents for C07D 417 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group (62,773)
05/2005
05/31/2005CA2195776C Novel process for the preparation of diisopinocampheylchloroborane
05/26/2005WO2005047526A2 Method for identifying inhibitors using a homology model of polo-like kinase 1
05/26/2005WO2005047273A1 Thiazole and pyrazole derivatives as flt-3 kinase inhibitors
05/26/2005WO2005047254A1 Octahydrophenanthrene hydrazinde derivatives useful as glucocorticoid receptor modulators
05/26/2005WO2005047247A1 Novel1,3-disubstituted azetidine derivatives for use as 5ht2a receptor ligands
05/26/2005WO2005047246A1 Novel 1, 3-disubstituted azetidine deivatives for use as 5ht2a receptor ligands
05/26/2005WO2005046688A2 Methods of use of thrombin receptor antagonists
05/26/2005WO2005046685A1 Substituted piperidines for the treatment of metabolic syndrome
05/26/2005WO2005000843A3 Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof
05/26/2005WO2004112719A8 Chemical compounds
05/26/2005WO2004108686A3 Benzimidazole compounds having hypoglycemic activity
05/26/2005US20050113430 2-[o-(aminoalkoxy)phenyl])-3-acylbenzothiazolines, e.g., 3-Acetyl-6-chloro-2-[2-(3-(N-(2-hydroxyethyl)-N-isopropylamino)-propoxy)-5-methoxyphenyl]benzothiazoline; treating pruritus or pain, particularly that caused by a rheumatic disease
05/26/2005US20050113429 E.g., 4-(2-methyl-3-oxo-hept-6-en-2-yl)-2,2-dimethyl-[1,3]-dioxane chemical intermediate; chemical/metabolic stabilization of microtubuli; antitumor, -carcinogenic agents; malignant melanoma, acute lymphocytic/myelocytic leukemia; angiogenesis inhibitors; antiinflammatory/-arthritic agents; psoriasis
05/26/2005US20050113423 Modulators of ATP-binding cassette transporters
05/26/2005US20050113422 5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-2,3-dihydro-indol-1-yl}-acetic acid methyl ester or an oxazole analogous compound; side effect reduction; non-insulin dependent diabetes; hypoglycemic agents; obesity; hyperlipemia; anticholesterol agents; atherosclerosis
05/26/2005US20050113420 Methionine aminopeptidase inhibitor
05/26/2005US20050113419 Therapeutic compounds for treating dyslipidemic conditions
05/26/2005US20050113417 Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
05/26/2005US20050113383 For therapy of allergy, allergy-induced airway responses, congestion, hypotension, cardiovascular disease, hypotension, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastrointestinal tract, obesity, sleep
05/26/2005US20050113378 As inhibitors of the retinoic acid-metabolism, as drugs; breast cancer; psoriasis
05/26/2005US20050113361 Amide derivatives as NMDA receptor antagonists
05/26/2005US20050113360 NMDA (N-methyl-D-aspartate) receptors; eg 6-(4-benzylpiperidin-1-carbonyl)-1,5-dihydro-oxazolo[4,5-f]indole-2-one
05/26/2005US20050113359 NMDA (N-methyl-D-aspartate) receptors; eg 1-[4-(4-fluoro-benzyl)-piperidin-1-yl]-1-(6-hydroxy-1H-indole-2-yl)methanone
05/26/2005US20050113358 Enzyme inhibitors for erectile dysfunction and sexual disorders
05/26/2005US20050113357 Cholinergic agents such as 3-[3-(4-methoxypiperidine)-1-yl-propyl]-1H-indole; for therapy of cognitive dysfunction, forgetfulness, confusion, memory loss, attention deficits, deficits in visual perception, depression, pain, sleep disorders, and psychosis
05/26/2005US20050113356 Inhibitors of cathepsin S
05/26/2005US20050113347 Novel antibacterial compounds: process for their preparation and pharmaceutical compositions containing them
05/26/2005US20050113341 Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis
05/26/2005US20050112487 electroconductive supports having layers containing azo compounds, charge transporting substance, acceptors and phenolic compounds, used in laser printer as well as high speed copiers
05/26/2005CA2545373A1 Novel 1,3-disubstituted azetidine derivatives for use as 5ht2a receptor ligands
05/26/2005CA2545350A1 Thiazole and pyrazole derivatives as flt-3 kinase inhibitors
05/26/2005CA2545060A1 Methods of use of thrombin receptor antagonists
05/26/2005CA2545020A1 Octahydrophenanthrene hydrazinde derivatives useful as glucocorticoid receptor modulators
05/25/2005EP1533310A1 Isonipecotamides for the treatment of integrin-mediated disorders
05/25/2005EP1532980A1 N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
05/25/2005EP1532138A1 Inhibitors of tyrosine kinases
05/25/2005EP1532132A1 Novel benzodioxoles
05/25/2005EP1532122A1 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
05/25/2005EP1532120A1 Phenylpyridazine derivatives as ligands for gaba receptors
05/25/2005EP1532115A2 Protease inhibitors
05/25/2005EP1532103A2 Use of compounds having an amine nucleus in manufacture of a medicament useful for treating factor viia-associated conditions
05/25/2005EP1531820A1 Anabaseine derivatives useful in the treatment of neurodegenerative diseases
05/25/2005EP1531815A1 Glucokinase activators
05/25/2005EP1531812A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis
05/25/2005EP1531811A2 Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer
05/25/2005EP1286673B1 Ligands of integrin receptors
05/25/2005EP1183247B1 Polycyclic thiazole systems and their utilization as anorectics
05/25/2005EP1140814B1 Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
05/25/2005EP1056724B1 Substituted cycloalkyl-4-oxonicotinic carboxamides; gaba brain receptor ligands
05/25/2005DE10348022A1 Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen New dipeptidyl peptidase IV inhibitors for the functional influence of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases
05/25/2005CN1620453A Thiazolidinedione derivative and its use as antidiabetic
05/25/2005CN1620447A Isochroman compounds for treatment of cns disorders
05/25/2005CN1620442A Five-membered-ring compound
05/25/2005CN1620435A 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
05/25/2005CN1620434A Pyrrolidine-2-ones as factor Xa inhibitors
05/25/2005CN1620424A Compounds for the treatment of inflammatory disorders
05/25/2005CN1620294A Pyrimidine A2b selective antagonist compounds, their synthesis and use
05/25/2005CN1620292A Broadspectrum heterocyclic substituted phenyl containing sulfonamide HIV protease inhibitors
05/25/2005CN1618797A New synthesis process of prisasin
05/25/2005CN1618796A 4, 5-disubstituted-2-(1-substituted-1 H-pyrrole-2-radical)-thiazole derivative
05/25/2005CN1618795A Process of preparing slereo iosmer of 1, 3-oxapantane kind nucleotide
05/25/2005CN1203070C Thrombin receptor antagonists
05/25/2005CN1203066C (Methylsulfonyl) phenyl-2-(5H)-furanones as cos-2 inhibitors
05/25/2005CN1202823C Use of thiazolidinedione for preventing or retaining non-insulin-dependent diabets mellitus (NIDDM) attack
05/25/2005CN1202821C Use of thiazolidinedione for preventing or retaining non-insulin-dependent diabets mellitus (MIDDM) attack
05/24/2005US6897321 Process for preparing azacycloalkanoylaminothiazoles (LD 137e)
05/24/2005US6897317 For therapy of arteriosclerosis and dyslipidaemias
05/24/2005US6897234 Asthma therapy; antiallergens; antiinflammatory agents
05/24/2005US6897232 Activate soluble guanylate cyclase; for use treating cardiovascular disorders, erectile dysfunction, diabetes, and cirrhosis of the liver, kidney disorders, and learning disability
05/24/2005US6897231 Jun n- terminal kinase inhibitors such as 3-(4-methoxyphenyl)-1H-indazole
05/24/2005US6897226 NK-1 receptor active amine oxide prodrugs
05/24/2005US6897219 Central nervous system diosrders; analgesics; antiinflammatory agents
05/24/2005US6897210 Anticancer agents; antiarthritic agents
05/24/2005US6897198 Method of treatment with combinations of statin and aryl-substituted propanolamine derivatives
05/24/2005US6896891 Non-systemic control of parasites
05/24/2005CA2169194C Substituted azadioxacycloalkenes and their use as fungicides
05/19/2005WO2005044797A1 Allosteric modulators of metabotropic glutamate receptors
05/19/2005WO2005044260A1 Use of crth2 antagonist compounds in therapy
05/19/2005WO2005021542A3 Process for the preparation of pioglitazone
05/19/2005WO2003049678A3 Mitotic kinesin inhibitors
05/19/2005US20050107616 Alpha-ketoamide derivatives as cathepsin k inhibitors
05/19/2005US20050107457 Indazole derivatives as JNK inhibitors and compositions and methods related thereto
05/19/2005US20050107449 Substituted thiazoles and oxazoles, e.g., 4-{1-[4-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid; treating atherosclerosis and diabetes and creating Syndrome X
05/19/2005US20050107442 Compounds that modulate PPAR activity and methods of preparation
05/19/2005US20050107440 Rosiglitazone edisylates and their use as antidiabetics
05/19/2005US20050107431 Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands
05/19/2005US20050107428 Antiinflammatory agents; autoimmune diseases; rheumatic diseases; anticholesterol agents; cardiovascular disorders
05/19/2005US20050107423 Quinolone antibiotics such as 1-Cyclopropyl-6-fluoro-7-(4-hydroxy-hexahydro-cyclopenta[c]pyrrol-2-yl)-8-methyl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid, used for treating gramnegative or grampositive bacterial infection in mammals
05/19/2005US20050107414 enzyme inhibitors such as N-(4-{4-[5-(2-Ethoxy-ethyl)-2,4,6-trioxo-hexahydro-pyrimidin-5-yloxy]-phenoxy}-benzyl)-acetamide, used for treating inflammation, cancers and other disorders
05/19/2005US20050107410 Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders
05/19/2005US20050107409 drugs such as 3-{[7-(2,5-dihydropyrrol-1-yl-carbonyl)-quinazolin-4-yl]aminomethyl}-4-hydroxy-benzamidine, used as anticoagulants
05/19/2005US20050107404 Mitotic kinesin inhibitors
05/19/2005US20050107403 Carbonylpyridine or carbonylpyrimindine compounds containing another nitrogen containing ring; useful in the treatment of inflammatory, metabolic or malignant conditions
05/19/2005US20050107392 treatment of disease such as diabetes, obesity, hyperlipidemia, and atherosclerotic disease; e.g. ethyl (5-methoxy-2,3-dihydro-1H-inden-1-ylidene)ethanoate
05/19/2005US20050107389 Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
05/19/2005US20050107388 Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain
05/19/2005US20050107381 e.g. 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-pyridin-2-yl-butyramide; inhibiting A beta -production; Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis, cerebral amyloid angiopathy, a prion-mediated disease, inclusion body myositis, stroke, multiple sclerosis and Down's Syndrome
05/19/2005US20050107379 antithrombolytic agents such as (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide, used for therapy of cardiovascular disorders
05/19/2005US20050107371 reduction of glucose, insulin, free fatty acids; treatment, control and prevention of diabetes, obesity, atherosclerosis, vascular inflammation and their related diseases; e.g. 7-[2-(5-Methyl-2-phenyl-4-oxazolyl)ethoxy]chromane-3-carboxylic Acid
05/19/2005US20050107370 Pyrrole derivatives as antimycobacterial compounds
1 ... 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 ... 628